Skip to content
drillr.ai
Sign up

BNTX

BioNTech SE

NASDAQ · Healthcare · Biotechnology · DE

$90.70
+4.35%
Ask drillr

  • Nov 3, 2026, 11:45 UTC

    BioNTech SE raised the midpoint of its full-year 2026 revenue guidance and updated its range to €1.7–1.9 billion.

    Source:

  • Nov 3, 2026, 11:45 UTC

    BioNTech SE reported third-quarter 2026 revenue of €1,289.2 million, adjusted R&D expenses of €578.5 million, and adjusted SG&A expenses of €178.5 million.

    Source:

  • Nov 3, 2026, 11:45 UTC

    BioNTech SE launched a variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season in multiple regions worldwide.

    Source:

  • Oct 27, 2026, 05:03 UTC

    Duality Biotherapeutics, Inc. announced clinical study results for elfetabart drozuntecan (DB-1311/BNT324, elfe-D) and DB-1310, including elfe-D combined with pumitamig and development progress in platinum-resistant ovarian cancer.

    Source:

  • Oct 25, 2026, 07:31 UTC

    BRISTOL MYERS SQUIBB CO and BioNTech SE announced positive global Phase 2 data for pumitamig in advanced non-small cell lung cancer that progressed after immunotherapy combined with chemotherapy.

    Source:

  • Oct 22, 2026, 10:45 UTC

    BioNTech SE and GILEAD SCIENCES, INC. announced a clinical trial collaboration and supply agreement to evaluate pumitamig with sacituzumab govitecan as first-line treatment for locally advanced or metastatic PD-L1-low or -negative triple-negative breast cancer.

    Source:

  • Oct 21, 2026, 04:30 UTC

    BioNTech SE officially opened a clinical-scale mRNA manufacturing and research facility at La Trobe University's campus in Bundoora, Melbourne.

    Source:

  • Oct 20, 2026, 10:45 UTC

    BioNTech announced that it will report its third-quarter 2026 financial results and provide a corporate update on November 3, 2026, with a conference call and webcast scheduled for 8:00 a.m. ET (2:00 p.m. CET).

    Source:

  • Oct 19, 2026, 10:45 UTC

    BioNTech SE announced that it will present new clinical data in 16 abstracts at the ESMO 2026 Congress in Madrid from October 23 to 27, 2026.

    Source:

  • Oct 13, 2026, 10:45 UTC

    BioNTech SE announced first topline results from the AHEAD-MERIT Phase 2/3 clinical trial of investigational mRNA cancer immunotherapy candidate BNT113 for metastatic HPV16-positive head and neck cancer.

    Source:

  • Oct 12, 2026, 16:16 UTC

    Shares of Moderna, Inc., BioNTech SE and NOVAVAX INC rallied following reports of a planned U.S.-led initiative to accelerate personalized cancer vaccines and expand research funding.

    Source:

  • Sep 28, 2026, 13:08 UTC

    BioNTech said it would close sites in Germany and Singapore after failing to find buyers as it pivots away from pandemic-era manufacturing.

    Source:

  • Sep 26, 2026, 04:30 UTC

    Pfizer is enforcing an April Belgian court ruling against Poland and Romania over unpaid COVID-19 vaccine orders by having Eurocontrol freeze transfers of airline route charges owed to their air navigation agencies.

    Source:

  • Sep 17, 2026, 17:30 UTC

    Health Canada approved the Pfizer-BioNTech COVID-19 vaccine adapted for the Omicron XBB variant.

    Source:

  • Sep 14, 2026, 08:00 UTC

    BioNTech and OncoC4 announced updated data from the non-pivotal stage 1 of the PRESERVE-003 Phase 3 trial showing gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients.

    Source:

  • Aug 28, 2026, 13:17 UTC

    BioNTech announced the termination of its Phase 2 clinical trial for colorectal cancer.

    Source:

  • Aug 27, 2026, 20:30 UTC

    The U.S. FDA approved the supplemental Biologics License Application for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant, for use in adults aged 65 and older and individuals aged 5-64 with high-risk conditions.

    Source:

  • Aug 20, 2026, 09:30 UTC

    BioNTech presented first global clinical data for its new dual-drug combination of Pumitamig and Elfetabart Drozuntecan in advanced lung cancer at the 2026 World Conference on Lung Cancer.

    Source:

  • Aug 11, 2026, 07:00 UTC

    Bios Life announced a multi-year partnership with Tempus, including commercial rights to BioNTech-InstaDeep's genomics AI.

    Source:

  • Aug 6, 2026, 11:00 UTC

    Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.

    Source:

  • Aug 4, 2026, 10:45 UTC

    BioNTech reported second quarter 2026 financial results with revenues of €105.6 million and revised its full year 2026 revenue guidance to €1.6–1.9 billion.

    Source:

  • Aug 3, 2026, 09:29 UTC

    BioNTech announced on Monday that Guido Oelkers, CEO of Sobi, will succeed Ugur Sahin as its chief executive.

    Source:

  • Jul 16, 2026, 11:30 UTC

    Arbutus Biopharma and its licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech.

    Source:

  • Jun 17, 2026, 06:38 UTC

    Moderna expressed interest in investing in production facilities in Germany, potentially acquiring plants that BioNTech plans to close.

    Source: